蓝帆医疗股份有限公司 2025年第七次临时股东会决议公告

Group 1 - The company held its seventh extraordinary general meeting of shareholders on December 29, 2025, with a total of 374 shareholders present, representing 307,776,294 shares, or 30.56% of the total shares [10][11] - The meeting was conducted in accordance with relevant laws and regulations, and no resolutions were rejected [3][10] - The company provided separate voting for minority shareholders to enhance their participation in significant decisions [2] Group 2 - The meeting approved several proposals, including the expected daily related party transactions for 2026, with 92.84% of the voting shareholders in favor [12] - The company also approved the expected credit and guarantee limits for 2026, with 97.65% of the voting shareholders in favor [15] - A proposal for purchasing liability insurance for directors and senior management was also approved, with 92.29% of the voting shareholders in favor [16] Group 3 - The company announced that the conversion price of its convertible bonds is expected to be adjusted downward due to the stock price being below 85% of the current conversion price for 10 consecutive trading days [21][35] - The current conversion price is set at RMB 9.50 per share, and the adjustment process will follow the established procedures [21][33] - The company will hold a board meeting to decide on the adjustment if the conditions are met, and will disclose the decision promptly [35][36]